Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BPMC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BPMC

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Blueprint Medicines Corp

BPMC
Current price
128.40 USD +0.09 USD (+0.07%)
Last closed 128.35 USD
ISIN US09627Y1091
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 8 299 894 272 USD
Yield for 12 month +11.41 %
1Y
3Y
5Y
10Y
15Y
BPMC
21.11.2021 - 28.11.2021

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Address: 45 Sidney Street, Cambridge, MA, United States, 02139

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

130.60 USD

P/E Ratio

Dividend Yield

Financials BPMC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BPMC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+508 824 000 USD

Last Year

+249 380 000 USD

Current Quarter

+149 413 000 USD

Last Quarter

+146 366 000 USD

Current Year

+488 661 000 USD

Last Year

+236 584 000 USD

Current Quarter

+146 611 000 USD

Last Quarter

+138 919 000 USD
EBITDA -158 367 008 USD
Operating Margin TTM -27.50 %
Price to Earnings
Return On Assets TTM -9.75 %
PEG Ratio
Return On Equity TTM -47.71 %
Wall Street Target Price 130.60 USD
Revenue TTM 562 121 024 USD
Book Value 5.30 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 55.50 %
Dividend Yield
Gross Profit TTM 542 347 008 USD
Earnings per share -2.52 USD
Diluted Eps TTM -2.52 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -99.40 %
Profit Margin -27.70 %

Stock Valuation BPMC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 14.55
Price Sales TTM 14.77
Enterprise Value EBITDA -11.22
Price Book MRQ 24.23

Technical Indicators BPMC

For 52 Weeks

73.04 USD 128.52 USD
50 Day MA 111.57 USD
Shares Short Prior Month 6 084 118
200 Day MA 97.63 USD
Short Ratio 0.62
Shares Short 3 128 839
Short Percent 5.45 %